Terlipressin Dilution for Intravenous Administration
Reconstitute each 0.85 mg vial of terlipressin with 5 mL of 0.9% Sodium Chloride Injection, USP before intravenous administration. 1
Preparation Instructions
The FDA-approved preparation method is straightforward:
- Each single-dose vial containing 0.85 mg terlipressin (equivalent to 1 mg terlipressin acetate) should be reconstituted with exactly 5 mL of 0.9% normal saline 1
- This is the only approved diluent specified in the drug label
- Discard any unused portion after reconstitution, as the formulation is preservative-free 1
Administration Details
Standard Dosing Regimen (FDA-Approved)
Days 1-3:
- Administer 0.85 mg (1 vial) IV every 6 hours 1
- Can be given through a peripheral line—no central line required 2
Day 4 Assessment:
- If serum creatinine decreased ≥30% from baseline: continue 0.85 mg every 6 hours
- If serum creatinine decreased <30% from baseline: increase to 1.7 mg (2 vials) every 6 hours
- If serum creatinine at or above baseline: discontinue 1
Important: Always flush the IV line after administration 1
Alternative Administration Method
While the FDA label specifies bolus dosing, emerging evidence strongly supports continuous infusion as a superior alternative with better safety profiles:
- Continuous infusion results in fewer adverse events (35% vs 62%) compared to bolus administration 3
- Requires lower total daily doses (mean 2.23 mg/day vs 3.51 mg/day for bolus) 3
- For continuous infusion: Start with 1 mg IV bolus, then 4 mg diluted over 24 hours 4, 5
- Recent consensus guidance recommends continuous infusion as the preferred route 6
Critical Safety Considerations
Pre-Administration Assessment
- Check oxygen saturation—do not give if SpO₂ <90% 2
- Assess for ACLF Grade 3 (≥3 organ failures)—use with extreme caution 2
- Screen for contraindications: active coronary/peripheral/mesenteric ischemia 2
- Avoid if serum creatinine >5 mg/dL (unlikely to benefit) 2
Monitoring During Treatment
- Sodium levels must be monitored closely—severe hyponatremia can develop rapidly (as low as 119 mmol/L within 72 hours) 7
- Monitor vital signs including pulse oximetry every 2-4 hours in low-risk patients 2
- Watch for respiratory failure (14% incidence in trials vs 5% placebo) 2
Common Pitfall
Judicious albumin use is essential—excessive albumin administration before or during terlipressin treatment increases risk of respiratory failure 2. While most trials used 20-40 g/day albumin, volume expansion benefits are likely achieved after only 1-2 days, so reassess volume status carefully 2.